The decision delays regulatory clearance for Bharat Biotech’s proposed phase III trial of MTBVAC, one of the world’s most advanced tuberculosis vaccine candidates and a potential successor to the century-old BCG
​The decision delays regulatory clearance for Bharat Biotech’s proposed phase III trial of MTBVAC, one of the world’s most advanced tuberculosis vaccine candidates and a potential successor to the century-old BCG by Soban News (international And National News)
